10x Genomics, Inc. — Director's Dealing 2022

Jan 5, 2022

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: 10x Genomics, Inc. (TXG)
CIK: 0001770787
Period of Report: 2022-01-03

Reporting Person: McAnear Justin J. (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2022-01-03	Class A Common Stock	M	10000	$5.04	Acquired	48819	Direct
2022-01-03	Class A Common Stock	S	3583	$145.1619	Disposed	45236	Direct
2022-01-03	Class A Common Stock	S	4083	$145.9556	Disposed	41153	Direct
2022-01-03	Class A Common Stock	S	1334	$146.9178	Disposed	39819	Direct
2022-01-03	Class A Common Stock	S	500	$148.0440	Disposed	39319	Direct
2022-01-03	Class A Common Stock	S	500	$149.1780	Disposed	38819	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2022-01-03	Stock Option (right to buy)	$5.04	M	10000	Disposed	2028-11-02	Class A Common Stock (10000)	Direct

Footnotes

F1: The transactions reported herein were effected pursuant to the Reporting Person's Rule 10b5-1 trading plan.

F2: This transaction was executed in multiple trades at prices ranging from $144.54 to $145.53. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F3: This transaction was executed in multiple trades at prices ranging from $145.54 to $146.48. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F4: This transaction was executed in multiple trades at prices ranging from $146.54 to $147.45. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F5: This transaction was executed in multiple trades at prices ranging from $147.58 to $148.36. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F6: This transaction was executed in multiple trades at prices ranging from $148.66 to $149.55. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.

F7: This option, originally for 600,000 shares, of which 249,841 shares have been exercised, vested as to 1/4th of the shares on October 8, 2019 and 1/48th of the shares subject to the option vest each month thereafter, subject to the Reporting Person continuing as a service provider through each such date.